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Abstract
The aim of this study is to consider the cost-effectiveness of a nurse-led, home-based inter-
vention (HBI) in cardiac patients with private health insurance compared to usual post-dis-
charge care. A within trial analysis of the Young@ Heart multicentre, randomized
controlled trial along with a micro-simulation decision analytical model was conducted to
estimate the incremental costs and quality adjusted life years associated with the home
based intervention compared to usual care. For the micro-simulation model, future costs,
from the perspective of the funder, and effects are estimated over a twenty-year time hori-
zon. An Incremental Cost-Effectiveness Ratio, along with Incremental Net Monetary Bene-
fit, is evaluated using a willingness to pay threshold of $50,000 per quality adjusted life year.
Sub-group analyses are conducted for men and women across three age groups sepa-
rately. Costs and benefits that arise in the future are discounted at five percent per annum.
Overall, home based intervention for secondary prevention in patients with chronic heart
disease identified in the Australian private health care sector is not cost-effective. The esti-
mated within trial incremental net monetary benefit is -$3,116 [95%CI: -11,145, $4,914];
indicating that the costs outweigh the benefits. However, for males and in particular males
aged 75 years and above, home based intervention indicated a potential to reduce health
care costs when compared to usual care (within trial: -$10,416 [95%CI: -$26,745, $5,913];
modelled analysis: -$1,980 [95%CI: -$22,843, $14,863]). This work provides a crucial impe-
tus for future research to understand for whom disease management programs are likely to
benefit most.
Introduction
Management of cardiovascular disease (CVD) in Australia costs $5.94 billion annually, approx-
imately 11% of total health care expenditure[1]. Significant financial pressure is emerging with
an increasing number of older individuals surviving an acute cardiac event but with residual
PLOSONE | DOI:10.1371/journal.pone.0144545 December 10, 2015 1 / 13
OPEN ACCESS
Citation: Byrnes J, Carrington M, Chan Y-K, Pollicino
C, Dubrowin N, Stewart S, et al. (2015) Cost-
Effectiveness of a Home Based Intervention for
Secondary Prevention of Readmission with Chronic
Heart Disease. PLoS ONE 10(12): e0144545.
doi:10.1371/journal.pone.0144545
Editor: Cathy Mihalopoulos, Deakin University,
AUSTRALIA
Received: June 11, 2015
Accepted: November 19, 2015
Published: December 10, 2015
Copyright: © 2015 Byrnes et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The Young@Heart trial was funded by
Bupa Australia. The funder had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have read the
journal's policy and the authors of this manuscript
have the following competing interests: The
Young@Heart trial was funded by Bupa Australia. JB,
PS, SS, YKC and MC have provided paid
risk for subsequent (and often costly) events. There are significant gaps in the overall applica-
tion of gold-standard secondary prevention[2] despite expert recommendations to prevent dis-
ease progression[3, 4]. Further, individual factors, such as treatment non-adherence, poor
knowledge, poor health literacy and sub-optimal self-care behaviors[5] are likely to contribute
to poorer longer-term impacts of traditional (and predominantly short-term) cardiac rehabili-
tation programs [6] notwithstanding practical issues such as insufficient access to prevention
programs following an acute cardiac event[7].
The Australian health care system is a hybrid of both a public system (no patient out of
pocket costs and with universal access to hospital treatment—all be it rationed through the use
of waiting lists) as well as a private health industry supported by private health insurance. The
private health insurance sector supports the public system through payments made on behalf
of insured patients. In 2010, this was more than six hundred million dollars. Individuals with
private health insurance (47% of the Australian population[8]) use more healthcare resources
with a greater frequency (e.g. primary care consultations and elective hospital procedures)[9].
Within this population, the Young@Heart Study aimed to examine the benefits of a tailored
disease management program.
The hypothesis of the Young @ Heart study is that a specialist nurse-led, multidisciplinary,
home-based intervention (HBI) program for individuals diagnosed with a chronic form of
heart disease and aged over 45 could reduce the rate of all-cause hospital days stay or all-cause
hospitalization. Whilst analysis of clinical outcomes from the trial have been previously
assessed[2], the aim of this study is to assess the cost-effectiveness of the Young @ Heart pro-
gram for the trial period as well as provide an assessment of the programs cost-effectiveness
beyond the duration of the trial based on modelled projections. Whilst overall group differ-
ences from the clinical trial were not statistically significant, the outcomes of the intervention
were predominantly worse for women. Alternatively, for men, HBI was associated with
reduced risk of cardiovascular-related hospitalization suggesting a sex-specific response to the
study intervention. It is unknown whether the intervention represents good value for money
either overall or when targeted specifically to those sub-groups for whom there was a greater
treatment effect. Consequently, this analysis will explore the cost and effectiveness for sub-
groups delineated by age and sex. As this intervention is targeted for patients with a chronic
disease, it is important that a modelled analysis be conducted to consider the long-term cost
and consequences of the intervention.
Methods
Young@Heart trial
The Young @ Heart Study was registered with the Australian New Zealand Clinical Trials Reg-
istry (No. 12608000014358) and conforms to both the principles outlined in the Declaration of
Helsinki [10] and the CONSORT guidelines[11]. The study was approved by the human
Research Ethics Committee of Uniting Care Health, Brisbane, Australia and all patients pro-
vided written informed consent to participate. The Young@Heart trial protocol and descrip-
tion of interventions have been previously described in full [12]. In short, the Young@Heart
Study was a multi-centre, randomised controlled trial of a nurse-led, home-based intervention
(HBI) program compared to usual care (UC). The HBI was offered to eligible members of a
large private health insurer who were recently hospitalised for chronic heart disease. Patients
(> = 45 years of age) were identified from their bedside in two hospitals. The intervention was
delivered through cardiac nurses specifically employed to deliver the intervention and was tai-
lored to an individual’s clinical stability, management and risk profile[13]. Based on their
home assessments and broader clinical profile of the patient, the cardiac nurses developed a
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detailed report and tailored health care plan for various members of the patient's health care
team as well as initiated a broad range of interventions to supplement the intervention. These
included referrals to primary care physicians, community pharmacists, dieticians, diabetes edu-
cators, cardiac rehabilitation programs or other allied health care service. HBI patients were
able to contact the cardiac nurse for continued advice and support and if readmitted to hospi-
tal, a repeat home visit at 7 to 14 days was implemented, accompanied by the preparation of a
revised health care plan. Overall, 602 (mean age 70 ± 10 years, 72% men) patients were ran-
domized to usual post-discharge care (UC, n = 296) or the same supplemented by HBI
(n = 306–96% received at least one home visit) between 1 July 2008 and 31 December 2009.
Previously published results from the Young@Heart trial at 2 years [2], reported that 42
patients (7.0%) had died and 492 patients (82%) were hospitalized with 2,338 all-cause admis-
sions and 10,045 days of hospitalization. There were no group differences (HBI vs. UC) in the
primary endpoints of all-cause hospital days stay or all-cause hospitalization. HBI outcomes
were predominantly worse for women. Alternatively, in men HBI was associated with reduced
risk of cardiovascular-related hospitalization suggesting a sex-specific response to the study
intervention. Consequently, analyses have been conducted on the basis of the entire trial popu-
lation as well as for sub-groups delineated by age and sex.
Within trial cost-effectiveness analysis
Analyses were conducted in Stata v.13.0 [14]. Costs and outcomes were both discounted at 5%
as per Australian health technology and decision-making bodies including the Pharmaceutical
Benefits Advisory Committee and Medical Services Advisory Committee. The analysis was
conducted from the perspective of the funder. A funder’s perspective has been adopted to
reflect the underlying investment decision to provide the intervention or not. Whilst a societal
perspective may illuminate the impact of the intervention on the broader health care system, it
does not assist the decision maker (in this case the health insurer). Moreover, whilst the Aus-
tralian health care landscape is a hybrid of private and public providers with both seeking to
maximise the health of those they represent, they do so with differing constraints and substan-
tially different optimisation problems. As such, a societal perspective is considered beyond the
scope of this assessment. The time horizon of analysis was two years (from baseline to
24-month follow up).
Costs. Costs included in this analysis were the sum of benefits paid by the insurer and
patient out of pocket costs associated with either services partially subsidised by the Govern-
ment or for re-hospitalisation episodes. Regression analysis of the total (discounted) cost per
patient as the dependent variable was conducted using a generalised linear model with trial
group allocation (UC or HBI) as the predictive variable. A gamma family, log-link model was
used given the skewed nature of health cost data. Age and sex were included as covariates.
Costs are reported in Australian dollars and were adjusted to 2013 dollar terms using the total
health price index[15].
The incremental cost per person randomised to receive the Young@Heart intervention was
$1,196 charged to the private insurer. This did not include the cost of any subsequent consulta-
tions associated with any referrals initiated as part of the intervention.
Outcomes. Quality Adjusted Life Years (QALYs) were estimated based on completion of
EuroQol—Five Dimension Three Level (EQ-5D-3L) Questionnaires[16] completed at baseline,
12 month follow-up and 24 month follow-up. Australian EQ-5D weights were applied to esti-
mate utility values for each time point[17]. Those who died were allocated a utility value of 0
and missing data were excluded from analysis. Within trial QALYs were calculated using area
under the curve analysis. Ordinary least squares regression analysis of individual QALYs was
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used to estimate the effect of receiving the intervention controlling for participants age and sex
as covariates.
Within-trial Incremental Cost Effectiveness Ratio and Net Monetary Benefit. The
incremental cost-effectiveness ratio (ICER) was estimated as the incremental costs divided by
the incremental QALYs. In this analysis, this was achieved by dividing the beta weight associ-
ated with being allocated to the intervention group from the regression equation for cost by the
beta weight associated with being allocated to the intervention from the regression equation for
QALYs. The ICER was compared to a willingness to pay per QALY of $50,000 (Australian dol-
lars), a commonly accepted value for health technology assessment in Australia [18]. Where
the cost per QALY (i.e. the ICER) is below the threshold (here, $50,000), the intervention can
be considered cost-effective, or represents ‘acceptable value for money’. However, where an
ICER is negative or where the 95% confidence interval for either cost or effect includes 0, the
preferred approach is to present the Incremental Net Monetary Benefit (INMB) instead of the
ICER. The INMB is equal to the incremental QALYs multiplied by the willingness to pay per
QALY less the incremental cost. The 95% confidence interval for the INMB was estimated
using bootstrapping. In addition to assessing cost-effectiveness by age and sex, one-way sensi-
tivity analyses were conducted with respect to the cost of the intervention ($600, $2,000 vs.
base case estimate of $1,196).
Modelled cost-effectiveness analysis beyond trial duration
A micro-simulation model (Fig 1) was constructed in TreeAge 2013 [19]. The model com-
prises of two health states, “Alive” and “Dead”. Simulated individuals begin in the “Alive”
health state and face the probability of death, probability of re-hospitalisation and probability
of remaining alive without having a re-hospitalisation. If an individual has a hospitalisation,
the hospitalisation was either cardiovascular related or another cause. Risk of death, hospitali-
sation and hospitalisation type (i.e. transition probabilities) are dependent on simulated indi-
viduals’ age, sex, allocated treatment group (usual care or intervention) and count of previous
re-hospitalisations (as they occur within the model). As the simulated individuals age or
incur either a cardiovascular or other hospitalisation, their subsequent risk of death, re-hospi-
talisation and probability that a hospitalisation is cardiovascular related (i.e. transition proba-
bilities) are revised. The advantage of a micro-simulation model of this nature enables
transition probabilities, cost and health related quality of life utility values to be determined
by the characteristics of the simulant (i.e. age, sex, treatment group) as well as the clinical his-
tory of the simulant (in this case number of hospitalisations and the reason for them). This
allows a simplified model structure with only two health states (alive or dead) whereas an
equivalent Markov model would require exponentially more. For example, a Markov model
would require mutually exclusive health states for: each hospitalisation event (i.e. first re-hos-
pitalisation, second re-hospitalisation); for both cardiac and other hospitalisation types
Fig 1. Overview of Model Structure.CVD: cardiovascular disease
doi:10.1371/journal.pone.0144545.g001
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(cardiac and other); as well as associated health-states to reflect every relevant combination of
previous hospitalisations (i.e. post first cardiac hospitalisation, post second cardiac hospitali-
sation, post one cardiac hospitalisation and one non-cardiac hospitalisation and so forth).
Simulated individuals were generated at random with respect to age and sex, based on respec-
tive distributions from baseline characteristics of the Young@Heart trial participants, and
identical simulated individuals were passed through the model for both home based and
usual care intervention.
Each model cycle was for one month to adequately reflect the timing of events observed in
the trial. The duration of the simulation model was for 20 years, or quasi-lifetime given that the
mean starting age of participants is 70. The analysis was conducted from the perspective of the
funder. Internal validity of the simulation model was assessed by running the model for the
same duration of the trial and comparing the simulated results with those of the trial.
Model parameters. Transition Probabilities: Transition probabilities were estimated
using regression analysis of events (death, hospitalisation and hospitalisation type) at 1 month,
months 2–6, months 7–12, months 12–24 and months 25 and over. This facilitated a non-lin-
ear risk of event over time. A Probit model was used for the dichotomous variable (event or no
event) at each time point and for the distribution between cardiovascular or non-cardiovascu-
lar hospitalisation (given a hospitalisation). Hospitalisation events excluded dialysis and any
other condition that the intervention was unlikely to affect (for example cancer) and were cate-
gorised as cardiovascular or non- cardiovascular related by expert nurse on review of the ICD-
10, AR-DRG codes and case record notes. Hospitalisation episodes with the same admission
date as the preceding hospitalisation discharge date were merged. The probability of an event
and hospitalisation type was assessed with respect to participant age, sex, randomisation group
and count of previous re-hospitalisations. Age, sex and treatment group transition probabilities
were then predicted from the resulting regression equation along with the average marginal
effect of a previous re-hospitalisation. Analyses were conducted in STATA 13.0 with robust
standard errors. Participants who died in a prior analysis period were removed from estimation
of subsequent risk of event calculations. Transition probabilities for beyond trial duration were
extrapolated for the model based on the 25 month and over regression equations. There is con-
sidered no missing data for hospital or death events.
Costs: A gamma, log-link Generalised Estimating Equation model was used to account for
the skew in episode cost data and multiple measures per trial participant. The costs included in
this analysis were equivalent to those considered in the within trial analysis. For hospital epi-
sodes that were merged, the costs of each hospitalisation were totalled. The regression model
estimated the cost per hospitalisation episode dependent on the age and sex of the trial partici-
pant, the count of previous re-hospitalisations and if the episode was cardiovascular related or
not. The age-sex adjusted cost per episode of a cardiovascular and non-cardiovascular hospita-
lisation was estimated along with the incremental cost increase (or decrease) for each previous
re-hospitalisation episode.
Utility: A Generalised Estimating Equation model was used to account for the multiple
measures per trial participant. The regression model estimated utility dependent on age and
sex of the trial participant, the count of previous re-hospitalisations for cardiovascular and the
count of previous non-cardiovascular related re-hospitalisations. Based on the regression equa-
tion, age-sex specific utility scores were estimated along with the average marginal increase or
decrease in utility associated with a cardiovascular or non-cardiovascular re-hospitalisation.
Modelled Incremental Cost Effectiveness Ratio. The incremental cost-effectiveness ratio
(ICER) was estimated as the incremental costs divided by the incremental QALYs. In this anal-
ysis, QALYs are estimated as the time (number of cycles) multiplied by the simulated individu-
als’ utility score (at each cycle). Costs were accrued for each hospitalisation episode. The ICER
CEA Cardiac Disease Management
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was determined from the difference in mean costs and QALYs between simulated individuals
receiving the home-based intervention or usual care. The simulation was undertaken for 1,000
simulated individuals.
Sensitivity Analysis: Distributions (standard errors) associated with each model parameter
are provided from the regression equations. Probabilistic sensitivity analysis was conducted
using Monte-Carlo simulation whereby the simulation model (of 1,000 individuals) is run
1,000 times. For each model run, a value for each model parameter was selected based on the
corresponding distribution and provided an estimated ICER. A 95% confidence interval for the
ICER was then estimated based on the 1,000 model runs.
Results
Within Trial Analysis Results
Costs. The predicted mean health care costs, controlling for age and sex, was $1,191 higher
for the HBI group compared to UC ($28,839 compared to $27,648) (Table 1). However, HBI
was associated with cost savings compared to UC for males aged over 75. This cost saving
($10,416) was greater than the cost to deliver the home based intervention ($1,196) (Table 1).
Outcomes. The predicted mean QALYs over the trial period, controlling for age and sex,
was 0.06 lower for HBI compared to UC (1.55 compared to 1.62) (Table 1). However, HBI was
associated with higher QALYs compared to UC for females aged between 65 and 75. However,
none of the differences in QALYs was statistically significantly different.
Table 1. Within Trial Predicted Mean Costs and QALYs: Home Based Intervention vs. Usual Care.
Sub-group Home Based Intervention Usual Care Difference in predicted means 95% Conﬁdence interval
Health care costs
Male
64 $21,052 $21,658 -$606 -$9,881 $8,670
65 74 $31,363 $26,995 $4,367 -$7,926 $16,660
75 $28,440 $38,598 -$10,158 -$26,474 $6,157
Female
64 $23,552 $20,260 $3,292 -$15,256 $21,840
65 74 $29, 131 $29,639 -$507 -$23,359 -$22,345
75 $40,125 $26,156 $13,969 -$4,953 $32,891
Persons $28,803 $27,633 $1,171 -$5,042 $7,383
Quality Adjusted Life Years
Male
64 1.80 1.81 -0.01 -0.19 0.17
65 74 1.48 1.64 -0.16 -0.33 0.01
75 1.42 1.50 -0.08 -0.27 0.12
Female
64 1.67 1.75 -0.08 -0.43 0.27
65 74 1.50 1.41 0.09 -0.23 0.41
75 1.44 1.46 -0.02 -0.25 0.21
Persons 1.56 1.62 -0.06 -0.15 0.03
Costs reported in Australian Dollars (2013)
QALY = quality adjusted life years
doi:10.1371/journal.pone.0144545.t001
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Within-trial Incremental Cost Effectiveness Ratio and Net Monetary Benefit. The
ICER for HBI compared to UC is negative (Table 2). Given the difficulties interpreting negative
ICERs, the net monetary benefit was also estimated. Based on a willingness to pay threshold of
$50,000 per QALY, HBI was associated with a negative net monetary benefit. However, for
males aged over 75 and females aged between 65 and 75, HBI was associated with positive
INMB. Although for both sub-groups, the estimated net monetary benefit was associated with
a significant degree of uncertainty. The results of the within trial analysis are not significantly
altered when the analysis is conducted with alternative intervention costs.
Simulation Model Results
Model parameters. Model parameters were derived using the predicted means based on
regression analyses of trial data. Results of the regression analyses are provided in Supporting
Information (S1 File).
Transition probabilities: The intervention was not a significant predictor of hospitalisation
or death. HBI was associated with less probability of a hospitalisation being cardiovascular;
however this was only statically significant for hospitalisations in the first month and for
months 7 to 18 (Supporting Information S1 File). The number of previous cardiovascular or
other hospital admissions statistically significantly increased the probability of a re-hospitalisa-
tion from months 24 and onwards but not for earlier time points. The number of previous car-
diovascular admissions were associated with a significant increase in the probability of
subsequent hospitalisations being cardiovascular related. Previous hospitalisations for other
causes were associated with a statistically significant decrease in subsequent hospitalisations
being cardiovascular. There was no statistically significant relationship between the number of
previous hospitalisation episodes (cardiovascular or other) and the probability of death.
Table 2. Within Trial ICER and INMB, Home Based Intervention vs. Usual Care.
Population ICER INMB
Mean (95% CI)
Male
64 $53,5892 $41 -$15,600 $15,681
65 74 -$27,5511 -$12,293 -$27,310 $2,724
75 $133,4282 $6,352 -$10,965 $23,668
Female
64 -$42,0211 -$7,209 -$38,082 $23,663
65 74 -$5,6603 $4,990 -$23,081 $33,061
75 -$725,6911 -$14,931 -$35,473 $5,610
Persons -$19,0011 -$4,251 -$12,025 $3,524
Sensitivity Analysis
Cost of intervention:
$600 -$9,3261 -$3,655 -$11,429 $4,120
$2,000 -$32,0521 -$5,055 -$12,829 $2,720
CI = conﬁdence interval; ICER = incremental cost effectiveness ratio; INMB = incremental net monetary beneﬁt
1 More costly and reduced Quality Adjusted Life Years
2 Less costly but reduced Quality Adjusted Life Years
3 Less costly and increased Quality Adjusted Life Years
doi:10.1371/journal.pone.0144545.t002
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Costs: Patient age and type of hospitalisation (cardiovascular) were statistically significantly
associated with a higher per episode cost of hospitalisation (Table 3). In addition, the number
of previous non-cardiovascular related hospitalisations were associated with a statistically sig-
nificant reduction in the per episode cost of subsequent hospitalisations. For probabilistic sen-
sitivity analysis, the cost of a hospitalisation and incremental cost per previous hospitalisation
were sampled from a gamma distribution.
Utilities: Patient age and number of hospitalisations were associated with a statistically sig-
nificantly lower health related quality of life score (Table 4). Cardiovascular hospitalisations
were associated with a 0.022 mean reduction in health related quality of life compared to a
0.012 reduction for other hospitalisations. For probabilistic sensitivity analysis, utility values
Table 3. Predicted Mean Cost per Hospitalisation and Incremental Cost Associated with Number of Previous Hospitalisations.
Age Cost of CV
hospitalisation, Mean,
(SE)
Increased cost of CV hospitalisation
per previous hospitalisation, Mean,
(SE)
Cost of Other
hospitalisation, Mean,
(SE)
Increased cost of other hospitalisation
per previous hospitalisation, Mean,
(SE)
Female
40 $8,796 ($2,108) $340 ($147) $6,051 ($1,238) $234 ($94)
50 $10,006 ($2,035) $387 ($159) $6,883 ($1,111) $266 ($101)
60 $11,382 ($2,002) $440 ($174) $7,830 ($985) $303 ($110)
70 $12,947 ($2,091) $500 ($194) $8,907 ($944) $344 ($122)
80 $14,727 ($2,412) $569 ($220) $10,131 ($1,120) $391 ($139)
90 $16,752 ($3,050) $647 ($254) $11,525 ($1,580) $445 ($161)
Male
40 $10,872 ($1,963) $420 ($168) $5,142 ($866) $199 ($76)
50 $12,367 ($1,729) $478 ($183) $5,849 ($716 $226 ($82)
60 $14,067 ($1,546) $544($201) $6,653 ($565) $257 ($90)
70 $16,002 ($1,617) $618 ($226) $7,568 ($536) $292 ($100)
80 $18,202 ($2,149) $703 ($259) $8,609 ($790) $333 ($115)
90 $20,705 ($3,157) $800 ($304) $9,793 ($1,292) $378 ($135)
Costs reported in Australian Dollars (2013)
CV = cardiovascular; Std. Error = robust standard error
doi:10.1371/journal.pone.0144545.t003
Table 4. Predicted Health Related Quality of Life Utility and Disutility Estimates.
Predicted Mean Std. Error Distribution
Age
40 0.97 0.02 Beta
50 0.93 0.02 Beta
60 0.89 0.01 Beta
70 0.85 0.01 Beta
80 0.81 0.01 Beta
90 0.77 0.02 Beta
Event
CV hospitalisation -0.022 0.010 Gamma
Other hospitalisation -0.012 0.003 Gamma
CV = cardiovascular; Std. Error = robust standard error
doi:10.1371/journal.pone.0144545.t004
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were sampled from a beta distribution whereas disutility associated with a hospitalisation event
were sampled from a gamma distribution.
Modelled Incremental Cost Effectiveness Ratio. The model predicts overall survival and
number of hospitalisations (by type) for the two treatment groups based on the input parame-
ters described above. HBI was associated with more cardiovascular hospitalisations and fewer
other hospitalisations (Table 5). Overall, HBI was associated with an increased cost ($9,288)
and fewer QALYs (-0.10) than usual care, thus resulting in a negative ICER of $97,506.
The greater majority of model iterations (61.1%) resulted in HBI being determined inferior
to UC. Of the remaining model iterations, 20.5% resulted in an ICER of less than $50,000 and
18.3% resulted in an ICER greater than $50,000 (Fig 2).
For males, the modelled results indicate an overall cost saving associated with the HBI (after
accounting for the cost of the intervention), however it was also associated with fewer QALYs
(Table 6). For females, the modelled results estimated HBI being associated with higher costs
and fewer QALYs.
Table 5. Model Outcomes and Incremental Cost-Effectiveness Ratio Over 20 Years.
Outcome Usual Care Home Based Intervention Home based Intervention vs. Usual Care
Death, n (%) 228 233 5
Hospitalisations per person
CV 1.67 2.63 0.96
Other 3.59 3.41 (0.18)
Cost per person, mean (95% CI) $34,759 $44,046 $9,288 ($2,884, $16,252)
QALYs per person, mean (SD) 9.11 9.02 (0.10) (-0.79, 0.56)
Incremental Cost Effectiveness Ratio ($97,506)
Net Monetary Beneﬁt ($10,172)
CI = conﬁdence interval; CVD = cardiovascular; SD = standard deviation;
doi:10.1371/journal.pone.0144545.t005
Fig 2. Probabilistic Sensitivity Analysis for Cost-effectiveness of Home Based Intervention vs. Usual
Care. Each dot represents a modelled incremental cost-effectiveness ratio; the eclipse represents the 95%
credible interval; the dashed line represents cost-effectiveness ratio equal to $50,000 per quality adjusted life
year. HBI: home based intervention. WTP: willingness to pay threshold. Incremental Effectiveness measured
in Quality Adjusted Life Years, Incremental Cost measured in Australian Dollars (2013)
doi:10.1371/journal.pone.0144545.g002
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Discussion
Based on the overall results of the Young@Heart Study, the application of a home-based sec-
ondary prevention program to supplement high quality usual care for privately insured
patients with chronic heart disease in Australia was associated with no statistically significant
or clinically meaningful changes in quality adjusted life years or in health care costs. Both the
within trial and modelled cost-effectiveness analyses conducted in this study indicate that the
HBI did not provide a statistically significant increase in quality adjusted life years. However,
consistent with the original report of gender differentials in outcome, for males (representing
around two thirds of the cohort) and in particular males 75 years and over (42% of males) HBI
indicated a potential to reduce health care costs when compared to usual care (within trial:
-$4,662 [95%CI: -$18,324, $8,999]; modelled analysis: -$1,980 [95%CI: -$22,843, $14,863]).
Thus, a clear need to identify the population that will benefit the most from a management
program has emerged.
However, these results are not in keeping with previous estimates of the cost-effectiveness of
disease management programs, but may reflect the specific population studied (i.e. those pri-
vately insured). A recent review [18] of model based analyses reporting the cost-effectiveness
of cardiovascular disease management programs found all included studies (n = 16) provided
improved health benefits relative to usual care with six of these studies also identifying disease
management programs as cost-saving. This may be explained by potentially diminishing mar-
ginal returns associated with new disease management programs. That is, as disease manage-
ment programs, or aspects of them, become increasingly implemented into usual care, the
marginal benefits of improved programmes may be less pronounced. Alternatively, as postu-
lated in the primary report, it may well reflect the health care environment in which the inter-
vention was applied and/or differences in the level of engagement with the cardiac nurses, (this
is the subject of ongoing analyses). Confirming the primary analyses, these data demonstrated
that differential patient cohorts (based on age and sex) may achieve relatively different out-
comes from the implementation of a disease management program. In the face of diminishing
marginal returns, the identification of patients most likely to benefit from disease management
programs will become increasingly important to ensure that the implementation of such pro-
grams are cost-effective. Notably, the disease management program appeared to be most cost-
Table 6. Modelled ICER and INMB, Home Based Intervention vs. Usual Care.
Population Δ Cost Δ QALY ICER INMB
Mean Lower 95% CI Upper 95% CI
Male
55 -$1,155 -0.09 $12,2912 -$3,542 -$136,168 -$2,793
65 -$1,664 -0.13 $12,4242 -$5,032 -$154,094 -$4,812
75 -$1,980 -0.15 $12,9972 -$5,636 -$80,693 -$3,948
Female
55 $6,104 -0.09 -$70,9011 -$10,407 -$13,951 -$4,570
65 $6,625 -0.07 -$95,2181 -$10,104 -$8,401 -$4,837
75 $7,023 -0.08 -$89,1721 -$10,960 -$6,283 -$1,725
CI = conﬁdence interval; ICER = incremental cost effectiveness ratio; INMB = incremental net monetary beneﬁt; QALY = quality adjusted life years; Δ =
incremental
1 More costly and reduced Quality Adjusted Life Years
2 Less costly but reduced Quality Adjusted Life Years
doi:10.1371/journal.pone.0144545.t006
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effective in older men and this demographic cohort represents the most predominant patient
group presenting with chronic heart disease.
This program has been investigated within an Australian population with private health
insurance. There remains significant points of differentiation between the Australian private
and public health care sectors[20] including patient socioeconomic and demographic charac-
teristics (including better self-reported health[21]). As such, the results from this analysis may
not necessarily be transferable to the broader public health care system; particularly given
favourable results from similar disease management programs targeting those with chronic
heart disease[22] and atrial fibrillation[23] in Australia. Moreover, the incremental benefit
associated with disease management programmes may, in Australia at least, be greater in the
public health care system than for those with private insurance; indeed a similar program
implemented in an equivalent cohort of cardiac patients in that setting demonstrated markedly
reduced hospital stay in both men and women [24].
This study is subject to a number of limitations that should be acknowledged. Firstly,
changes in pharmaceutical and medical service costs were not captured in this analysis.
Whilst it is likely that a home based intervention may provide the necessary support and tools
to optimise pharmacological treatment, the cost implications are unclear. On the other hand,
disease management programs could be associated with increased costs from higher utilisa-
tion of medical services due to: increased level health screening, awareness and where provid-
ing referrals to supplementary services are elements of the intervention itself. As such, these
estimates may underestimate the total costs associated with the home-based intervention in
this study. Secondly, this analysis has focused on the health related quality of life information
collected during the trial and modelled future health related quality of life with respect to hos-
pitalisations. This approach, whilst best representing the clinical trial evidence, does not
include other significant improvements associated with the home based intervention from
the clinical trial (including reductions in: body weight, waist circumference, total cholesterol,
systolic and diastolic blood pressure). However, none of these improvements are significantly
different to those achieved with usual care. Thus, whilst the fullness of benefits may not have
been captured in this analysis, the incremental benefits of home based intervention compared
to usual care is not likely to be significantly biased. Finally, the model considered hospitalisa-
tion and death as mutually exclusive events. For those that die during a hospitalisation event,
the model considers these to have occurred in two separate cycles. Given that the cycle length
within the model is 30 days it is unlikely that this will significantly alter the results estimated.
Moreover, there is no reason to believe that such cases occurred more or less frequently in the
intervention arm compared to usual care and as such, will not bias the incremental results
presented here.
Despite these limitations, this work provides a crucial impetus for the continuation of
efforts to improve the evidence base regarding appropriate patient selection and design of dis-
ease management programs. Future innovation within disease management programs is
likely to be driven by a priori identification and targeting of disease management programs,
or their components, to patients most likely to achieve benefits that outweigh the costs of the
program; with particular consideration of the health care system within which the program is
being applied.
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